325 Results

People

  1. Lacouture
    Lacouture
  2. Kris
    Kris
  3. Hudis
    Hudis
  4. Motzer
    Motzer
  5. Saltz
    Saltz
  6. Seidman
    Seidman
  7. Heelan
    Heelan
  8. Kelsen
    Kelsen
  9. Ilson
    Ilson
  10. Norton
    Norton

Groups

  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)
  7. Dermatology Service (41)
  8. Dermatology (41)
  9. Hematologic Malignancies, Division of (36)
  10. Surgery (34)
  1. "alopecia"
Formats
  1. Journal Article (301)
  2. Review (14)
  3. Conference Paper (5)
  4. Research Letter (3)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (244)
  2. Solid Tumor Oncology Division (195)
  3. Survivorship Research (84)
  4. Gastrointestinal Oncology Service (57)
  5. Breast Medicine Service (46)
  6. Division of Subspecialty Medicine (45)

More Groups

People
  1. Mario Lacouture (38)
  2. Mark Kris (20)
  3. Clifford Hudis (15)
  4. Andrew Seidman (14)
  5. Leonard Saltz (14)
  6. Robert Motzer (14)

More People

Years
  1. 2025 (7)
  2. 2024 (20)
  3. 2023 (16)
  4. 2022 (11)
  5. 2021 (11)
  6. 2020 (14)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Cancer (14)
  3. Lancet Oncology (13)
  4. Clinical Cancer Research (12)
  5. Investigational New Drugs (11)
  6. Gynecologic Oncology (10)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. American Society of Clinical Oncology (35)
  3. Springer (31)
  4. Elsevier Science, Inc. (20)
  5. Wiley Blackwell (20)
  6. Oxford University Press (19)

More Publishers

Results (325)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion study
    Journal Article

    Sullivan, R. J.; Infante, J. R.; Janku, F.; Lee Wong, D. J.; Sosman, J. A.; Keedy, V.; Patel, M. R.; Shapiro, G. I.; Mier, J. W.; Tolcher, A. W.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer
    Journal Article

    Dunn, L. A.; Fury, M. G.; Sherman, E. J.; Ho, A. A.; Katabi, N.; Haque, S. S.; Pfister, D. G.
    Head & Neck (2018)

    Fulltext@MSK | Save
  • Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
    Journal Article

    Algazi, A. P.; Esteve-Puig, R.; Nosrati, A.; Hinds, B.; Hobbs-Muthukumar, A.; Nandoskar, P.; Ortiz-Urda, S.; Chapman, P. B.; Daud, A.
    Pigment Cell & Melanoma Research (2018)

    Fulltext@MSK | Save
  • Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
    Journal Article

    Javle, M.; Lowery, M.; Shroff, R. T.; Weiss, K. H.; Springfeld, C.; Borad, M. J.; Ramanathan, R. K.; Goyal, L.; Sadeghi, S.; Macarulla, T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
    Journal Article

    Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: A PIDTC natural history study
    Journal Article

    Heimall, J.; Logan, B. R.; Cowan, M. J.; Notarangelo, L. D.; Griffith, L. M.; Puck, J. M.; Kohn, D. B.; Pulsipher, M. A.; Parikh, S.; Martinez, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
    Journal Article

    Lowery, M. A.; Yu, K. H.; Kelsen, D. P.; Harding, J. J.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Cancer (2017)

    Fulltext@MSK | Save
  • Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
    Journal Article

    Momtaz, P.; Harding, J. J.; Ariyan, C.; Coit, D. G.; Merghoub, T.; Gasmi, B.; You, D.; Viale, A.; Panageas, K. S.; Samoila, A.; more...
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Haas, N. B.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Melichar, B.; Rini, B. I.; Choueiri, T. K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save